Abstract 5635
Background
A cancer diagnosis often causes an emotional impact with signs of anxiety, uncertainty and subjective discomfort. It´s necessary to identify and assess emotional discomfort to offer quality treatment articulated around the patient and his / her demand. The design of a questionnaire that is easy to use and understand, allows the detection of patients susceptible to referral to the Psycho-oncology Unit (POU).
Methods
- Prepare a PAQ that includes: Evaluation of emotional distress assisted by visual analogue scales (VAS); Modified Gijón scale (sociofamilar assessment scale); previous use of psychoactive drugs - Include PAQ in the first nursing visit - Quick referral to POU - Interview with psycho-oncology nurse - Valuation, diagnosis and treatment planning by POU - Data recording - Data analysis.
Results
Patients with a positive PAQ are referred to the POU where the liaison nurse performs an interview with the patient and / or family. The nurse collects data on psychobiography, oncological disease, psychic sphere, frequent affections, previous contacts with psychologists / psychiatrists and treatments with psychoactive drugs. The POU will offer the patient the most appropriate resource for their needs (Psychotherapy, Psychopharmaceuticals, and Social Work Service).
Conclusions
The inclusion of the PAQ in the first visit of nursing allows the detection and early treatment of disorders in the psychosocial area. We achieve an optimal use of resources, a greater adherence to the proposed oncological treatment, alleviate problems that are found throughout the oncological treatment and improve the quality of life of our patients by reducing emotional discomfort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract